GlassScriptPhysician profile
Hira Bakhtiar
NPI 1588076707
$1,382.13
in general payments reported to CMS, 2019-2025
14 companies · $757 in 2025
The $757 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $17.30 · 2021: $93.21 · 2022: $35.45 · 2023: $52.95 · 2024: $427 · 2025: $757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786 · Education: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.97 |
| Education | $450.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $312.05 | 2024-2025 | Dupixent |
| Genzyme Corporation | $275.76 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $232.07 | 2021-2025 | Fasenra, Tezspire |
| Jazz Pharmaceuticals INC. | $224.49 | 2025 | |
| Verona Pharma, INC. | $51.57 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $51.47 | 2024-2025 | Lumryz |
| Insmed, INC. | $44.53 | 2025 | Brinsupri, Arikayce |
| Merck Sharp & Dohme LLC | $43.31 | 2024 | Keytruda |
| Viatris Specialty LLC | $39.05 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $28.32 | 2025 | Nucala |
| Mylan Specialty L.P. | $23.83 | 2024 | Yupelri |
| Caris Mpi, INC. | $22.23 | 2025 | Mi Cancer Seek |
| Harmony Biosciences LLC | $17.30 | 2020 | |
| Electromed, INC. | $16.15 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hira Bakhtiar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.